Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?

doi:10.1111/bjh.17699

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?

British journal of haematology - 1 Oct 2021

Durot Eric, Delmer Alain

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Myeloid Differentiation Factor 88
Share to Waldenstrom Macroglobulinemia

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 34472092
DOI: 10.1111/bjh.17699

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?PMID 34472092Read ↗

Waldenström macroglobulinaemia: the key questions.Semantic proximity Read ↗

The real world of Waldenström's macroglobulinaemia.Semantic proximity Read ↗

Survival Trends in Waldenström Macroglobulinemia and Comparison of Outcomes with the General US PopulationSemantic proximity Read ↗

Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.Semantic proximity Read ↗

Not preventing--yet, just avoiding Tay-Sachs disease.Semantic proximity Read ↗

Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemiaSemantic proximity Read ↗

Erythropoietin receptor mutation--a rush of blood to the head?Semantic proximity Read ↗

Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.